Consumer Genetic Results in the Clinic: What Labs Need to Confirm Before Acting
Short answer: Consumer genetic results should be treated as a prompt for clinical testing, not as a diagnosis. FDA documentation for 23andMe's BRCA report says results should be confirmed in a clinical setting before medical action. With about one in ten users receiving an actionable result, labs should build a confirmation, documentation, and billing workflow now.
Why are consumer genetic results reaching clinics now?
On October 26, 2026, the 23andMe Research Institute announced an analysis of nearly 6 million research-consented U.S. participants who received FDA-authorized Genetic Health Risk reports between 2017 and 2025. The reports covered 91 variants in 20 genes across 14 conditions. According to the release, presented at the American Society of Human Genetics 2026 meeting in Montréal, more than 635,000 people, or 10.6 percent, received at least one medically actionable result.
The same release says 93.8 percent of participants opted in to receive their reports and that more than 52,000 results involved genes on the ACMG secondary findings list. It also cites a 2026 Genetics in Medicine Open study in which 86 percent of actionable results shared with a healthcare professional led to at least one medical recommendation, and 88 percent of those recommendations were followed. The release does not describe confirmatory testing, and it does not present the analysis as peer reviewed, so the figures are best read as a signal of volume rather than a clinical benchmark.
The supply side is growing too. Labcorp announced on July 27, 2026 a Marker by Labcorp Genetic Health Panel, available through Labcorp OnDemand from August 3, 2026. It analyzes 163 genes tied to more than 100 medically actionable conditions, includes access to a licensed genetic counselor, and states that results are not diagnostic and should be considered with medical history. Whatever the channel, patients will increasingly arrive with a result in hand and a question for their physician.
What conditions are driving the volume?
The 23andMe counts are concentrated outside hereditary cancer. The release reports more than 430,000 results for inherited blood clotting disorders (F2 and F5), more than 100,000 for hereditary hemochromatosis (HFE), more than 21,000 for cardiovascular conditions (including LDLR, APOB, and TTR), and nearly 11,800 for hereditary cancer (including BRCA1, BRCA2, and MUTYH).
For laboratories, that mix matters. Thrombophilia and hemochromatosis findings may arrive with limited clinical context, and coverage for such testing is tightly defined at the Medicare contractor level. Our review of the MolDX hereditary thrombophilia LCD is a useful reminder that a consumer finding alone does not establish medical necessity.
What do FDA labeling and published data say about confirmation?
The FDA documentation for the 23andMe BRCA1/BRCA2 report (K223597) is direct. It states that the test does not diagnose cancer or any other health condition and should not be used to make medical decisions, and that results should be confirmed in a clinical setting before taking any medical action. It lists 44 detected variants, 24 in BRCA1 and 20 in BRCA2, against more than 1,000 BRCA1/BRCA2 variants known to increase cancer risk, and notes that a negative result does not rule out other cancer-related variants. The record also contains internally inconsistent variant counts in places, so cite the 44-variant figure with care.
Published data show why the confirmation language is not boilerplate. In a Genetics in Medicine study by Ambry Genetics employees, 49 patient requests for clinical confirmation of consumer-test results were reviewed, and 40 percent of the variants reported in the raw data were not present on confirmation. That study looked at raw data from consumer platforms rather than FDA-authorized reports, so it does not measure the error rate of authorized reports. It does show the risk when raw files are passed into clinical workflows without verification.
How should a lab handle a consumer report that arrives with an order?
A practical workflow has four steps. First, classify what the patient is bringing: an FDA-authorized report, a raw data file, or a third-party interpretation of raw data. Each carries different reliability. Second, order a clinical-grade assay that covers the gene in question, ideally within a panel that fits the personal and family history, rather than a narrow single-variant check when broader testing is indicated. Our guide to NCCN hereditary cancer testing guidelines explains how appropriateness is usually judged.
Third, report clearly. The clinical report should state the genes and variant classes assessed, so a negative clinical result is not misread as contradicting a consumer report without explanation, and a discordant result is documented as such. Fourth, plan for reclassification and recontact, as discussed in our piece on hereditary cancer retesting after negative panels.
Genes on the ACMG secondary findings list add a reporting dimension for labs that perform exome or genome sequencing. See our overview of ACMG secondary findings reporting for the policy questions that follow.
What are the billing and coverage risks?
The sources reviewed here do not describe a payer rule specific to consumer-initiated findings, so labs should not assume one. The risks are familiar. Medical necessity must stand on documented clinical facts, such as personal and family history, rather than on the existence of a consumer report alone. Repeat-order logic can trigger edits if a patient has had prior testing, as covered in our guide to duplicate lab test denials and modifier 91. Patients may also face out-of-pocket cost, so financial counseling before collection is prudent.
Revenue cycle teams can track orders prompted by consumer results as a separate category for a quarter, recording payer, denial reason, and appeal outcome. That gives a lab its own coverage evidence instead of assumptions. For workflow support across ordering, documentation, and claims, visit ScreenMyGene.
What should medical directors and genetic counselors do now?
Medical directors can set a written policy for how the lab treats outside consumer data, including a statement that such data is not used as a reportable result. Genetic counselors can prepare plain-language materials for ordering clinicians explaining why confirmation is needed and what a discordant result means. Requisition forms can add a field for the source of any prior consumer finding, so that the order record shows why testing was requested.
Ordering clinicians will also benefit from knowing which findings are time-sensitive. A BRCA or TTR finding raises different follow-up questions than an F5 or HFE finding, and the lab can help by offering clear test menus and turnaround information rather than leaving clinicians to guess.
Frequently asked questions
Is a consumer genetic report a diagnostic result?
No. The FDA documentation for 23andMe's BRCA1/BRCA2 report states that the test does not diagnose cancer and that results should be confirmed in a clinical setting before taking any medical action. Labs should treat consumer reports as history to verify, not as an order basis.
How common are actionable consumer results?
In a 23andMe analysis announced October 26, 2026, 10.6 percent of nearly 6 million U.S. participants received at least one medically actionable result. It is a company announcement from a self-selected research cohort, so rates may differ in clinic populations.
Why does raw consumer data need confirmation?
An Ambry Genetics study in Genetics in Medicine found that 40 percent of variants reported in consumer raw data were not present on clinical confirmation, across 49 patient requests. That study examined raw data rather than FDA-authorized reports, but it shows why confirmation matters.
Will payers cover confirmatory testing after a consumer result?
It varies by payer and policy, and the sources reviewed here did not describe a specific rule for consumer-initiated findings. Labs should check the applicable policy, document medical necessity such as family history, and counsel patients about possible out-of-pocket cost before collection.
What should a requisition capture when a consumer report prompts testing?
Capture the source of the finding, the gene and variant reported, whether it came from a report or raw data, relevant family history, and the clinical decision the result could change. This documentation supports medical necessity review and reduces repeat-order confusion.
This article is for educational purposes only and does not constitute legal, regulatory, billing, or clinical advice. Coverage varies by payer and plan; confirm requirements with the applicable policy and your compliance counsel.
Sources: 23andMe Research Institute press release, "More Than 1 in 10 People Receive Medically Actionable Genetic Results Through 23andMe" (GlobeNewswire, October 26, 2026); Labcorp press release, "Labcorp Launches Marker by Labcorp Genetic Health Panel" (July 27, 2026); FDA De Novo/510(k) documentation K223597 for the 23andMe BRCA1/BRCA2 Genetic Health Risk Report; Tandy-Connor S et al., "False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care," Genetics in Medicine (2018), PMID 29565420.